Zonisep 25 Capsule contains Zonisamide 25 mg, an anticonvulsant medication primarily indicated for the management of partial seizures in patients with epilepsy. Zonisamide exerts its therapeutic effect by stabilizing neuronal membranes and suppressing abnormal electrical activity in the brain through modulation of voltage-gated sodium and calcium channels, as well as inhibition of carbonic anhydrase. This dual mechanism contributes to its efficacy in reducing seizure frequency and severity. Zonisep 25 is typically administered orally, with dosage individualized based on clinical response and tolerability. It is important to initiate treatment at a low dose and titrate gradually to minimize adverse effects. Common side effects may include dizziness, somnolence, headache, and gastrointestinal disturbances, while serious but less frequent adverse reactions include metabolic acidosis, hypersensitivity reactions, and renal calculi. Caution is advised in patients with sulfonamide allergy, hepatic or renal impairment, and in those with a history of kidney stones. Regular monitoring of renal function, electrolytes, and bicarbonate levels is recommended during prolonged therapy. Zonisep 25 Capsule should be used under strict medical supervision, ensuring adherence to prescribed dosing to optimize seizure control and minimize risks.